Belzutifan extension trial aims to extend lives in VHL and advanced cancer
NCT ID NCT07405164
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This extension study follows people with von Hippel-Lindau (VHL) disease or advanced solid tumors who are already taking belzutifan in another trial. The goal is to see how long they live and how safe the drug is over the long term. About 450 participants will take belzutifan by mouth daily until their disease gets worse or side effects become too severe.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Belzutifan (a drug that blocks a protein helping tumors grow)
What this could lead to
If successful, this trial could show that belzutifan helps people with VHL disease or advanced solid tumors live longer while managing their cancer over time.
What could go wrong
This is an extension study, so it only includes people already on belzutifan. It is not testing a new treatment, and results may not apply to everyone. Side effects are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Asan Medical Center ( Site 2900)
RECRUITINGSeoul, 05505, South Korea
Contact Phone: •••-•••-••••
-
Beth Israel Deaconess Medical Center ( Site 0107)
RECRUITINGBoston, Massachusetts, 02215, United States
Contact Phone: •••-•••-••••
-
CNCE Precarpathian Clinical Oncologic Center ( Site 2600)
ACTIVE_NOT_RECRUITINGIvano-Frankivsk, Ivano-Frankivsk Oblast, 76018, Ukraine
-
Dana-Farber Cancer Institute ( Site 0105)
RECRUITINGBoston, Massachusetts, 02215, United States
Contact Phone: •••-•••-••••
-
Département clinique de médecine de laboratoire du CHUM ( Site 0001)
RECRUITINGMontreal, Quebec, H3T 1E2, Canada
Contact Phone: •••-•••-••••
-
Fakultni nemocnice Olomouc-Onkologicka klinika ( Site 1000)
RECRUITINGOlomouc, 77900, Czechia
Contact Phone: •••-•••-••••
-
Hadassah Medical Center ( Site 1604)
RECRUITINGJerusalem, 9112001, Israel
Contact Phone: •••-•••-••••
-
Hospital Universitari Vall d'Hebron ( Site 2300)
RECRUITINGBarcelona, 08035, Spain
Contact Phone: •••-•••-••••
-
Hospital Universitario 12 de Octubre ( Site 2301)
RECRUITINGMadrid, 28041, Spain
Contact Phone: •••-•••-••••
-
Isala, locatie Zwolle ( Site 1902)
RECRUITINGZwolle, Overijssel, 8025 AB, Netherlands
Contact Phone: •••-•••-••••
-
Karmanos Cancer Center ( Site 0108)
RECRUITINGDetroit, Michigan, 48201, United States
Contact Phone: •••-•••-••••
-
Kyushu University Hospital ( Site 3101)
RECRUITINGFukuoka, 812-8582, Japan
Contact Phone: •••-•••-••••
-
ME І.І. Mechnykov Dnipro Regional Clinical Hospital ( Site 2601)
ACTIVE_NOT_RECRUITINGDnipropetrovsk, Dnipropetrovsk Oblast, 49005, Ukraine
-
N.N. Blokhin NMRCO ( Site 2101)
ACTIVE_NOT_RECRUITINGMoscow, Moscow, 115478, Russia
-
Országos Onkológiai Intézet-Urogenitális Tumorok és Klinikai Farmakológiai Osztály ( Site 1501)
RECRUITINGBudapest, 1122, Hungary
Contact Phone: •••-•••-••••
-
Rabin Medical Center ( Site 1602)
RECRUITINGPetah Tikva, 4941492, Israel
Contact Phone: •••-•••-••••
-
Rambam Health Care Campus ( Site 1600)
RECRUITINGHaifa, 3109601, Israel
Contact Phone: •••-•••-••••
-
Russian Scientific Center of Radiology and Surgical Technologies ( Site 2100)
ACTIVE_NOT_RECRUITINGSaint Petersburg, Sankt-Peterburg, 197758, Russia
-
START San Antonio ( Site 0104)
RECRUITINGSan Antonio, Texas, 78229, United States
Contact Phone: •••-•••-••••
-
Samsung Medical Center ( Site 2902)
RECRUITINGGangnam, Seoul, 06351, South Korea
Contact Phone: •••-•••-••••
-
Severance Hospital, Yonsei University Health System ( Site 2901)
RECRUITINGSeodaemun-gu, Seoul, 03722, South Korea
Contact Phone: •••-•••-••••
-
Sheba Medical center ( Site 1601)
RECRUITINGRamat Gan, 5265601, Israel
Contact Phone: •••-•••-••••
-
Sourasky Medical Center ( Site 1603)
RECRUITINGTel Aviv, 64239, Israel
Contact Phone: •••-•••-••••
-
Taipei Veterans General Hospital ( Site 2800)
ACTIVE_NOT_RECRUITINGTaipei, 11217, Taiwan
-
Tampereen yliopistollinen sairaala ( Site 1305)
RECRUITINGTampere, Pirkanmaa, 33520, Finland
Contact Phone: •••-•••-••••
-
The Christie NHS Foundation Trust ( Site 2501)
RECRUITINGManchester, M20 4BX, United Kingdom
Contact Phone: •••-•••-••••
-
UZ Leuven ( Site 0900)
RECRUITINGLeuven, Vlaams-Brabant, 3000, Belgium
Contact Phone: •••-•••-••••